{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:01:02Z","timestamp":1778842862107,"version":"3.51.4"},"reference-count":38,"publisher":"SLACK, Inc.","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Ann"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>\n            Hepatitis is defined as inflammation of the liver. This inflammation can be acute and self-limited, chronic (leading to cirrhosis and an increased risk for hepatocellular carcinoma), or fulminant (requiring lifesaving liver transplantation). Although there are many causes of hepatitis, this article focuses on the main childhood viral hepatidities: types A, B, C, D, and E. This review discusses the main characteristics of each virus, including salient epidemiology, clinical characteristics, diagnosis, treatment, and prevention strategies.\n            <jats:bold>\n              [\n              <jats:italic>Pediatr Ann<\/jats:italic>\n              . 2016;45(12):e420\u2013e426.]\n            <\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/19382359-20161114-01","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T21:09:56Z","timestamp":1481749796000},"source":"Crossref","is-referenced-by-count":6,"title":["Viral Hepatitis in Children: A Through E"],"prefix":"10.3928","volume":"45","author":[{"given":"Ankur","family":"Chugh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryann","family":"Maximos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryl","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regino P.","family":"Gonzalez-Peralta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2009.01.005"},{"key":"e_1_3_1_3_2","unstructured":"World Health Organization. Hepatitis A. Updated July 2016. http:\/\/www.who.int\/mediacentre\/factsheets\/fs328\/en\/. Accessed November 15 2016."},{"key":"e_1_3_1_4_2","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis. Hepatitis A infection. http:\/\/www.cdc.gov\/hepatitis\/hav\/. Updated August 27 2015. Accessed November 15 2016."},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145454"},{"key":"e_1_3_1_6_2","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Advisory Committee on Immunization Practices (ACIP)","year":"2006","unstructured":"Advisory Committee on Immunization Practices (ACIP)Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1\u201323.","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_1_7_2","first-page":"1080","article-title":"Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Advisory Committee on Immunization Practices Centers for Disease Centers for Disease Control and Prevention (CDC)","year":"2007","unstructured":"Advisory Committee on Immunization Practices Centers for Disease Centers for Disease Control and Prevention (CDC). Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56:1080\u20131084.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_1_8_2","first-page":"906","volume-title":"Pediatric Gastrointestinal and Liver Disease","author":"Fawaz R","year":"2015","unstructured":"Fawaz R, Jonas MM. Acute and chronic hepatitis. In: , Wyllie R, Hyams J, Kay M, eds. Pediatric Gastrointestinal and Liver Disease. 5th ed. Philadelpia, PA: Elsevier; 2015:906\u2013919.","edition":"5"},{"key":"e_1_3_1_9_2","unstructured":"World Health Organization. Hepatitis B. Updated July 2016. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/. Accessed November 15 2016."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.03.036"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21612"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318258328d"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.09.023"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27978"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i44.7880"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.05.002"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0192"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20030"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909163411202"},{"key":"e_1_3_1_21_2","unstructured":"American Association for the Study of Liver DiseasesInfectious Diseases Society of America. HCV guidance: recommendations for testing managing and treating hepatitis C. www.hcvguidelines.org. Accessed November 16 2016."},{"key":"e_1_3_1_22_2","unstructured":"World Health Organization. Hepatitis D. Updated July 2016. www.who.int\/mediacentre\/factsheets\/hepatitis-d\/en. Accessed November 30 2016."},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12217"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-013-0365-x"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000859"},{"key":"e_1_3_1_26_2","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis \u2013 Hepatitis E information. www.cdc.gov\/hepatitis\/hev\/hevfaq.htm. Updated December 18 2015. Accessed November 30 2016."},{"key":"e_1_3_1_27_2","unstructured":"World Health Organization. Hepatitis E. Updated July 2016. http:\/\/www.who.int\/mediacentre\/factsheets\/fs280\/en\/. Accessed November 23 2016."},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-1-200707030-00005"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25505"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706992"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2009.00552.x"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.13-0265"},{"key":"e_1_3_1_33_2","unstructured":"Hoffmann-La Roche. An open-label study of pegasys in combination with lamivudine in children with hbeag-positive chronic hepatitis b in the immune-tolerant phase. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02263079?term=NCT02263079&rank=1. Accessed November 22 2016."},{"key":"e_1_3_1_34_2","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Entecavir\/pegylated interferon in immune tolerant children with chronic hepatitis B virus (HBV) infection. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01368497?term=NCT01368497&rank=1. Accessed November 22 2016."},{"key":"e_1_3_1_35_2","unstructured":"Gilead Sciences. Safety and efficacy of ledipasvir\/sofosbuvir fixed dose combination +\/-ribavirin in adolescents and children with chronic HCV-infection. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02249182?term=NCT02249182&rank=1. Accessed November 22 2016."},{"key":"e_1_3_1_36_2","unstructured":"AbbVie. A study to evaluate treatment of hepatitis C virus infection in pediatric subjects (ZIRCON). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02486406?term=NCT02486406&rank=1. Accessed November 22 2016."},{"key":"e_1_3_1_37_2","unstructured":"Gilead Sciences. Safety and efficacy of sofosbuvir + ribavirin in adolescents and children with genotype 2 or 3 chronic HCV infection. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02175758?term=NCT02175758&rank=1. Accessed November 22 2016."},{"key":"e_1_3_1_38_2","unstructured":"Centers for Disease Control and Prevention. Figure 2.1 Reported number of acute hepatitis A cases -- United States 2000\u20132012. http:\/\/www.cdc.gov\/hepatitis\/statistics\/2012surveillance\/index.htm#tabs-497521-4. Accessed November 30 2016."},{"key":"e_1_3_1_39_2","unstructured":"Centers for Disease Control and Prevention. Figure 3.1 Reported number of acute hepatitis B cases -- United States 2000\u20132012. http:\/\/www.cdc.gov\/hepatitis\/statistics\/2012surveillance\/index.htm#tabs-501433-5. Accessed November 30 2016."}],"container-title":["Pediatric Annals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/pediatrics\/journals\/pedann\/2016-12-45-12\/%7Bd7093a7b-8dc2-44fd-96fa-63848fb641fa%7D\/viral-hepatitis-in-children-a-through-e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:53:13Z","timestamp":1683075193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/19382359-20161114-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.3928\/19382359-20161114-01"],"URL":"https:\/\/doi.org\/10.3928\/19382359-20161114-01","relation":{},"ISSN":["0090-4481","1938-2359"],"issn-type":[{"value":"0090-4481","type":"print"},{"value":"1938-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}